Last reviewed · How we verify
Safety and Performance of the Glyconics-SX System (ANODE01)
The main clinical study objective is to retrieve initial high quality spectra measurements indicative of the accuracy of the Glyconics-SX System in distinguishing between individuals with or without T2DM based on known and/or assumed clinical status of the participants and as controlled by values of an internal biomarker indicative of glycaemia, HbA1c, as measured with validated, comparator device.
Details
| Lead sponsor | Glyconics Ltd |
|---|---|
| Phase | NA |
| Status | COMPLETED |
| Enrolment | 100 |
| Start date | Mon Aug 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Oct 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Diabetes Mellitus, Type 2
Interventions
- Near-infrared (NIR)
Countries
United Kingdom